华芢\生物招股 拟全球发售1764.88万股H股

Core Viewpoint - Huazhen Biotech plans to conduct an IPO from December 12 to December 17, 2025, aiming to issue 17.6488 million H-shares, with approximately 10% allocated for public offering in Hong Kong and 90% for international offering, including a 15% over-allotment option [1] Group 1: Company Overview - Established in 2012, Huazhen Biotech is a Chinese biopharmaceutical company focused on developing protein drugs, primarily targeting wound healing therapies [1] - The core products include rhPDGF-BB drugs, with Pro-101-1 for burn treatment and Pro-101-2 for diabetic foot treatment [1] - As of the latest practical date, the company has ten candidate products, seven of which are PDGF candidates [1] Group 2: IPO Details - The offering price per share is expected to range from HKD 38.2 to HKD 51, with trading on the Hong Kong Stock Exchange anticipated to commence on December 22, 2025, at 9:00 AM (Hong Kong time) [1] - Assuming a median offering price of HKD 44.60 and no exercise of the over-allotment option, the net proceeds from the global offering are estimated to be approximately HKD 709 million [1] Group 3: Use of Proceeds - Approximately 61.8% of the proceeds will be allocated to the continued clinical development and commercialization of core products Pro-101-1 and Pro-101-2 [1] - About 18.8% will be used to enhance research and development capabilities through equipment purchases [1] - Approximately 6.3% will fund ongoing preclinical development of PDGF products outside the core products, such as fresh wounds, pressure ulcers, and radiation ulcers [1] - Around 3.1% will be directed towards preclinical research activities for Mes-201, Oli-101, and Oli-201 [1] - About 10.0% will be reserved for working capital and general corporate purposes [1]